EP1418919A4 - Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires - Google Patents

Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires

Info

Publication number
EP1418919A4
EP1418919A4 EP02747054A EP02747054A EP1418919A4 EP 1418919 A4 EP1418919 A4 EP 1418919A4 EP 02747054 A EP02747054 A EP 02747054A EP 02747054 A EP02747054 A EP 02747054A EP 1418919 A4 EP1418919 A4 EP 1418919A4
Authority
EP
European Patent Office
Prior art keywords
inotophoresis
fluorourcil
bulbar
peri
eyelid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02747054A
Other languages
German (de)
English (en)
Other versions
EP1418919A2 (fr
Inventor
Stephen Warren
Steven Hamilton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Iomed LLC
Original Assignee
Iomed LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iomed LLC filed Critical Iomed LLC
Publication of EP1418919A2 publication Critical patent/EP1418919A2/fr
Publication of EP1418919A4 publication Critical patent/EP1418919A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Ophthalmology & Optometry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP02747054A 2001-07-20 2002-07-19 Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires Withdrawn EP1418919A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US30678801P 2001-07-20 2001-07-20
US306788P 2001-07-20
PCT/US2002/022860 WO2003007798A2 (fr) 2001-07-20 2002-07-19 Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires

Publications (2)

Publication Number Publication Date
EP1418919A2 EP1418919A2 (fr) 2004-05-19
EP1418919A4 true EP1418919A4 (fr) 2007-06-13

Family

ID=23186840

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02747054A Withdrawn EP1418919A4 (fr) 2001-07-20 2002-07-19 Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires

Country Status (4)

Country Link
EP (1) EP1418919A4 (fr)
JP (1) JP2004535462A (fr)
AU (1) AU2002316724A1 (fr)
WO (1) WO2003007798A2 (fr)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0549702A (ja) * 1991-08-28 1993-03-02 Teijin Ltd イオントフオレシス用装置
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
EP0927560A1 (fr) * 1998-01-05 1999-07-07 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorèse
WO1999040967A1 (fr) * 1998-02-13 1999-08-19 Hadasit Medical Research Services & Development Company Ltd. Dispositif d'administration de medicaments par ionophorese
WO2000051620A1 (fr) * 1999-03-02 2000-09-08 Vitreo-Retinal Technologies, Inc. Agents destines a etre administres par voie intravitreenne pour traiter ou prevenir des troubles oculaires
WO2001091853A1 (fr) * 2000-05-31 2001-12-06 Biophoretic Therapeutic Systems, Llc Dispositif electrocinetique d'administration de medicaments
WO2003007961A1 (fr) * 2001-07-20 2003-01-30 Iomed, Inc. Methodes permettant de traiter des irregularites oculaires neoplasiques, angiogeniques, fibroplastiques et/ou immuno-suppressives par l'administration de medicaments a base de methotrexate et dispositifs iontophoretiques oculaires destines a administrer lesdits medicaments a base de methotrexate

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6245759B1 (en) * 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0549702A (ja) * 1991-08-28 1993-03-02 Teijin Ltd イオントフオレシス用装置
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
EP0927560A1 (fr) * 1998-01-05 1999-07-07 Optisinvest Dispositif pour le transfert intraoculaire de produits actifs par iontophorèse
WO1999040967A1 (fr) * 1998-02-13 1999-08-19 Hadasit Medical Research Services & Development Company Ltd. Dispositif d'administration de medicaments par ionophorese
WO2000051620A1 (fr) * 1999-03-02 2000-09-08 Vitreo-Retinal Technologies, Inc. Agents destines a etre administres par voie intravitreenne pour traiter ou prevenir des troubles oculaires
WO2001091853A1 (fr) * 2000-05-31 2001-12-06 Biophoretic Therapeutic Systems, Llc Dispositif electrocinetique d'administration de medicaments
WO2003007961A1 (fr) * 2001-07-20 2003-01-30 Iomed, Inc. Methodes permettant de traiter des irregularites oculaires neoplasiques, angiogeniques, fibroplastiques et/ou immuno-suppressives par l'administration de medicaments a base de methotrexate et dispositifs iontophoretiques oculaires destines a administrer lesdits medicaments a base de methotrexate

Also Published As

Publication number Publication date
WO2003007798A2 (fr) 2003-01-30
WO2003007798A3 (fr) 2003-06-19
JP2004535462A (ja) 2004-11-25
EP1418919A2 (fr) 2004-05-19
AU2002316724A1 (en) 2003-03-03

Similar Documents

Publication Publication Date Title
EP1592435A4 (fr) Formulation ophtalmique pour la prevention et le traitement de pathologies oculaires
AU2002348336A1 (en) Accommodating pupil non-concentricity in eyetracker systems
SI1496912T1 (sl) Kombinacija brimonidina in timolola za topikalno oftalmološko uporabo
AU5704201A (en) Improving vision and retinal imaging
EP1392292A4 (fr) Pyranoindazoles et leur utilisation dans le traitement du glaucome
EP2311949A3 (fr) Composés anti-sens ciblés contre les connexines et procédés d'utilisation associés
AU3365401A (en) Use of ketotifen as ophthalmic agent
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
AU2002240463A1 (en) Use of endostatin in the treatment of ocular neovascularization
AU2002232437A1 (en) Ophthalmic lubricating solution adapted for use in lasik surgery
AU2003269413A1 (en) Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
WO1998039293A3 (fr) 13-thia prostaglandines destinees a etre utilisees dans la therapie du glaucome
AU2002331606A1 (en) Non-invasive ocular assessment method and associated apparatus
AU2002366791A1 (en) Composition for treating contact lenses in the eye
EP1558238A4 (fr) Beta-hydroxyphenylaldylamines et utilisation de celles-ci pour traiter le glaucome
EP1455780A4 (fr) Nouveaux derives de benzodifurane imidazoline et de benzofurane imidazoline et leur utilisation pour traiter le glaucome
EP1418919A4 (fr) Utilisation de 5 fluorourcil, administre par iontophorese en tant qu'inhibiteur de la proliferation cellulaire dans l'oeil, la conjonctive bulbaire et palpebrale, la paupiere, les tissus mous et la peau periorbitaires
CA2353527A1 (fr) Utilisation de stimulateurs des facteurs neurotrophiques pour le traitement des affections neurodegeneratives ophtalmiques
AU2001261748A1 (en) Antibiotic compositions for treatment of the eye, ear and nose
WO2002036096A8 (fr) Produits viscoelastiques transitionnels ne necessitant pas d'aspiration destines a la chirurgie
IL151683A0 (en) Composition for use in treatment of ocular hypertension and glaucoma
AU2002350828A1 (en) Use of dendrimers in an ophthalmic composition
ZA200302911B (en) Method and composition for treatment of ocular hypertension and glaucoma.
AU2003216547A8 (en) Compositions and methods for treating glaucoma and ocular hypertension
AU2002257819A1 (en) Ophthalmic compositions comprising chitosan and an active substance, in particular ketotifen, and use thereof for the treatment of ocular allergic conditions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040219

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

RIN1 Information on inventor provided before grant (corrected)

Inventor name: HAMILTON, STEVEN

Inventor name: WARREN, STEPHEN

A4 Supplementary search report drawn up and despatched

Effective date: 20070511

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 27/02 20060101ALI20070507BHEP

Ipc: A61N 1/30 20060101ALI20070507BHEP

Ipc: A61K 31/513 20060101AFI20070507BHEP

RBV Designated contracting states (corrected)

Designated state(s): DE FR GB IT

17Q First examination report despatched

Effective date: 20071019

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080303